When the US Food & Drug Administration convened an advisory committee to consider the conversion to traditional approval for Eisai Co., Ltd./Biogen, Inc.’s Leqembi (lecanemab) for Alzheimer’s disease, the agency decided to think small: the roster included just six voting members.
That is the smallest advisory committee for an application review in recent memory. In fact, it is well below the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?